Medigene AG maintained earnings guidance for 2024. For the year, company expects revenue to be between EUR 9 Million and 11 Million (unchanged) in 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.275 EUR | -1.92% | -3.77% | -16.39% |
05-21 | Medigene, BioNTech Extend Cancer Immunotherapy Partnership | MT |
05-21 | Medigene AG's Global Research & Collaboration Agreement with BioNTech SE to Extend Beyond Initial Announced Term | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.39% | 41.25M | |
+18.15% | 124B | |
+18.02% | 111B | |
-12.75% | 23.17B | |
+5.07% | 22.94B | |
-39.94% | 17.42B | |
-9.86% | 17.42B | |
-14.97% | 16.9B | |
+2.80% | 13.71B | |
+27.39% | 11.82B |
- Stock Market
- Equities
- MDG1 Stock
- News Medigene AG
- Medigene Ag Maintains Earnings Guidance for 2024